GOSS News and Press, Gossamer Bio Inc. From 10/13/20

Gossamer Bio (GOSS) -32% after two studies in GB001, Phase 2B LEDA trial in eosinophilic asthma and Phase 2 TITAN trial in chronic rhinosinusitis, failed to meet the primary endpoints.Wah Fu Education (WAFU) -23%.Hexindai (HX) -20%.Medley Management (MDLY) -19%.I...

Gossamer Bio (GOSS) announced that two studies in GB001, Phase 2B LEDA trial in eosinophilic asthma and Phase 2 TITAN trial in chronic rhinosinusitis, failed to meet the primary endpoints.The 480-subject LEDA study did not meet the primary endpoint of asthma worsening. Tho...

Gossamer Bio (GOSS) has announced new data from GB004's Phase 1b study, on the reduction of fecal calprotectin, an inflammatory biomarker in inflammatory bowel disease ((IBD)), and the resolution of rectal bleeding, which is considered to be an objective measure of disease activity. Data were...

- Newly disclosed data build on topline results and continue to support GB004’s differentiated approach of targeting epithelial barrier restoration in patients with ulcerative colitis - - GB004 demonstrated superior barrier protection compared to tofacitinib in pre-clin...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data relevant to GB004 at ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to...

SAN FRANCISCO and CINCINNATI, Sept. 1, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today dosing of the first patient with razuprotafib in the I-SPY COVID Trial (NCT0448...

- GB001: Phase 2 studies, LEDA in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in the second half of 2020 - - GB002: Expected to commence Phase 2 TORREY study in pulmonary arterial hypertension in the second half of 2020 - - GB004: Exp...

CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, and diabetic complications, will releas...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to...